• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Nightingale Health

0.83 EUR-2.12 %10.7. klo 18.29
4,744 following

HEALTH

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
-2.12 %
-2.80 %
-36.25 %
-58.27 %
-59.41 %
-68.18 %
-0.95 %
-85.66 %
-83.84 %

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more
Market cap
50.7M EUR
Turnover
46.39K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
12.06.2026
Disclaimer
Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Do you have any actual, substantive criticism to offer as well? A new person who comes to the forum to showcase their own brilliance and educational background without providing any other content is, by definition, a so-called spammer. Best regards, a layperson shareholder of Nightingale...
yesterday
by Farseer
6
I replied to that user named Inspector1. All of their posts in this thread are complete zero-content filler.
yesterday
by Farseer
4
I have been following the investment discussions surrounding Nightingale since its IPO. What has made these discussions challenging is that the science and technology at the core of Nightingale’s business are clearly more complex than those of the majority of Finnish listed companies...
yesterday
by The Ugly Buckling
4
It’s a bit dramatic to dismiss it as an advertisement right off the bat. Using a neutral prompt, I asked Google’s NotebookLM tool to present the findings of the studies in plain language and explain their significance for healthcare and Nightingale’s business operations. I don’t ...
7/10/2026, 3:57 PM
by The Ugly Buckling
2
Was this directed at me? If so, my questions were sincere and I thought that those wiser than me would speculate on whether it’s needed and, if it is, how/how much/when, perhaps? I apologize if the question was somehow offensive. I am a complete novice and didn’t know that you’re...
yesterday
by Matsku
1
I think this is an interesting and valuable discussion on how AI can be utilized in a generally acceptable way to analyze a company like Nightingale, and specifically on how AI-generated results should be shared, or if they should be shared at all. If NotebookLM allows sharing the...
yesterday
by The Ugly Buckling
1
This AI piece seems more like an advertisement for NG than a summary of a scientific article. How many seconds will it take for “headquarters” to have this removed? Advertisements should be clearly labeled; otherwise, it’s considered native advertising, and that’s likely prohibited...
7/9/2026, 6:54 PM
by Sakuoulu
1
Read more on our forum
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 12.06.2026

Latest extensive report

Released: 13.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
16.9.
2026

Annual report '26

5.11.
2026

General meeting '26

9.3.
2027

Interim report Q2'27

Press release01.07.2026 klo 16.00

Nightingale Health and Archipelago Health partner to bring preventive screening to small-island health systems in the Crown Dependencies, Bermuda and the Caribbean

Nightingale Health
Regulatory press release29.06.2026 klo 18.15

Nightingale Health’s Board of Directors resolved on new stock option program

Nightingale Health
Nightingale: We factored the project delay into our estimates
Research12.06.2026 klo 10.20 by
Antti Siltanen, Antti Luiro

Nightingale: We factored the project delay into our estimates

The revenue outlook for the next fiscal year exceeds 10 MEUR.

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Nightingale's profit warning: Project delay shifts revenue to next year
Analyst Comment09.06.2026 klo 09.40 by
Antti Siltanen

Nightingale's profit warning: Project delay shifts revenue to next year

The company's business appears to be progressing in line with our estimates.

Nightingale Health
Regulatory press release08.06.2026 klo 19.25

Inside information, profit warning: Nightingale Health continues to grow but will not reach its 50% growth target this financial year as about EUR 2 million of revenue shifts to next financial year

Nightingale Health
Nightingale: Nightingale sings to a deaf market
Research04.06.2026 klo 09.36 by
Antti Siltanen

Nightingale: Nightingale sings to a deaf market

The low valuation compensates for the very high level of risk.

Nightingale Health
Nightingale joins wellbeing services county research project
Analyst Comment29.05.2026 klo 09.46 by
Antti Siltanen

Nightingale joins wellbeing services county research project

Nightingale's risk screening selects participants for lifestyle coaching.

Nightingale Health
Press release28.05.2026 klo 11.00

Nightingale Health joins South Savo Wellbeing Services County's preventive healthcare research project in Finland

Nightingale Health
Regulatory press release27.05.2026 klo 16.45

Nightingale Health Plc’s financial reporting and Annual General Meeting in financial year 2026–2027

Nightingale Health
New partnership for Nightingale
Analyst Comment25.05.2026 klo 09.11 by
Antti Siltanen

New partnership for Nightingale

The new memorandum of understanding will expand blood analysis to the longevity programs in Switzerland and South Africa as early as this summer.

Nightingale Health
Press release22.05.2026 klo 09.30

Nightingale Health and Formula 100 Health partner in preventive health: Embedding multi-disease risk detection across longevity programmes in Switzerland and South Africa

Nightingale Health
Regulatory press release21.05.2026 klo 17.25

Nightingale Health Plc – Managers’ Transactions – Olli Karhi

Nightingale Health
Regulatory press release18.05.2026 klo 13.02

Nightingale Health Plc: Flagging notification in accordance with Chapter 9, Section 10 of the Securities Markets Act (Cor Group Oy)

Nightingale Health
US market roadmap for medical devices – a European perspective
Analyst Comment27.03.2026 klo 12.45 by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Nightingale H1'26: Research projects accelerate H2
Research06.03.2026 klo 11.44 by
Antti Siltanen

Nightingale H1'26: Research projects accelerate H2

Nightingale's major research projects will generate revenue in H2.

Nightingale Health
Nightingale, Webcast, Half-year financial report 1 July–31 December 2025
Webcast05.03.2026 klo 14.00

Nightingale, Webcast, Half-year financial report 1 July–31 December 2025

Nightingale Health
Regulatory press release05.03.2026 klo 09.00

Nightingale Health's half-year report: Delivering clinical value for healthcare and moving toward 50% revenue growth, supported by a strong sales pipeline

Nightingale Health
Nightingale H1'26 preview: Revenue still relies on research projects
Analyst Comment03.03.2026 klo 09.11 by
Antti Siltanen

Nightingale H1'26 preview: Revenue still relies on research projects

We expect revenue to grow, driven by research projects and the Terveystalo collaboration.

Nightingale Health
A step forward for Nightingale in New York
Analyst Comment10.02.2026 klo 08.50 by
Antti Siltanen

A step forward for Nightingale in New York

The New York laboratory permit allows tests to be offered to healthcare providers without separate FDA approval.

Nightingale Health
Regulatory press release09.02.2026 klo 21.30

Inside information: Nightingale Health achieves major milestone in the United States: New York laboratory now holds a clinical laboratory permit from New York State

Nightingale Health